Cannabinoid Safety and Regulation Act

Summary

Creates a federal regulatory framework for cannabinoid products under the Food, Drug, and Cosmetic Act, including new definitions, prohibited acts (such as sales to persons under 21 and mixing cannabinoids with alcohol/tobacco), inspection and enforcement authorities, and a requirement that agencies issue joint recommendations for THC-containing beverages. Expands public-health surveillance and grant programs to address cannabis use and polysubstance harms, funds competitive grants to prevent underage cannabis use, and establishes federal research, prevention, and state grant programs to study and reduce cannabis-impaired driving with multi-year appropriations.

• Establishes a new FDA-centered regulatory regime for cannabinoid products and adds specific prohibited acts, enforcement tools, and definitions.
• Prohibits sales of cannabinoid products to persons under 21 and restricts combining cannabinoids with alcohol, tobacco, or nicotine products.
• Requires interagency recommendations for regulation of THC-containing beverages within 60 days, allocating labeling, taxation, and safety authorities.
• Expands public health surveillance to include cannabis-related adverse effects and increases grant funding for prevention and surveillance.
• Creates a competitive grant program to prevent underage cannabis use with $25M/year for FY2026–2030 and prioritizes underserved communities.
• Directs DOT/NHTSA to study cannabis-impaired driving, launch a National Roadside Survey, run prevention campaigns, and report results to Congress.
• Creates a State cannabis-impaired driving prevention grant program with $40M/year for FY2026–2030 and a federal share schedule tied to state open-container laws.
• Appropriates $30M/year for DOT/NHTSA research/prevention and adds $100M/year for expanded public-health grant authorities for FY2026–2030.
• Imposes new compliance, labeling, packaging, and testing expectations on cannabinoid product manufacturers, retailers, and distributors.